News & Views
Collaboration extends Development Programme targets
Oct 06 2020
An expansion to its existing multi-target collaboration agreement with LG Chem, the life sciences division of the South Korean LG Group, will see Avacta’s Affimer XT™ serum half-life extension system incorporated into a new programme of biotherapeutics development that could potentially bring milestone payments of up to $55m to Avacta Group.
The extension of the partnership, original established in December 2018, includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totalling $98.5m for two therapeutics to be developed using the Affimer XT technology. LG Chem also has the exclusive rights to develop and commercialise these new products on a world-wide basis.
Avacta Group chief executive Dr Alastair Smith said: “I am delighted with this expansion to the agreement with LG Chem, with whom we have developed a strong collaborative partnership. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative therapies.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK